Feinstein Institutes’ John M. Kane Receives 2026 Schizophrenia International Research Society Lifetime Achievement Award
John M. Kane, MD, a leading figure in schizophrenia research and co-director of the Institute of Behavioral Science at Northwell Health’s Feinstein Institutes for Medical Research, has been honored with the 2026 Lifetime Achievement Award by the Schizophrenia International Research Society (SIRS). The prestigious recognition highlights his decades of groundbreaking contributions that have significantly advanced the scientific understanding, clinical management, and global outcomes for individuals living with schizophrenia.
The SIRS Lifetime Achievement Award is regarded as one of the highest distinctions in the field of schizophrenia research. It is awarded to individuals whose careers demonstrate sustained excellence and transformative impact across scientific discovery, clinical innovation, and global mental health advancement. Dr. Kane received the award during the SIRS Annual Conference held in March in Florence, Italy, where leading researchers and clinicians from around the world gathered to share advances in schizophrenia and related disorders.
Dr. Kane is widely recognized as one of the foremost pioneers in modern schizophrenia research. In addition to his role as co-director of the Institute of Behavioral Science, he serves as a professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Over the course of his distinguished career, he has also held several senior leadership positions within Northwell Health, including serving as chair of Psychiatry for 34 years at Zucker Hillside Hospital in Glen Oaks and as senior vice president for Behavioral Health Services. His leadership has helped shape one of the most influential academic and clinical psychiatry programs in the United States.
Throughout his career, Dr. Kane’s work has focused on multiple dimensions of schizophrenia research and care, including the psychobiology of the disease, early intervention strategies, recovery-oriented treatment models, and efforts to improve both the quality and cost-effectiveness of psychiatric care systems. In recent years, he has also played an active role in integrating digital technologies into mental health care, aiming to enhance monitoring, treatment personalization, and long-term patient outcomes.
Upon receiving the award, Dr. Kane expressed deep appreciation for the recognition, emphasizing that his work has been shaped and inspired by patients, families, colleagues, mentors, and trainees. He described the honor as especially meaningful because it reflects peer recognition from within the global scientific community dedicated to advancing schizophrenia research and care. He noted that contributing to the field over many decades has been both a professional privilege and a personal commitment to improving the lives of those affected by severe mental illness.
Dr. Kane’s scientific contributions are extensive and highly influential. He has served as the principal investigator on 24 grants funded by the U.S. National Institutes of Health (NIH), underscoring his longstanding role as a leader in federally supported psychiatric research. Among his most notable achievements is his leadership of the NIH-funded Recovery After an Initial Schizophrenia Episode (RAISE) program, a landmark initiative designed to improve outcomes for individuals experiencing first-episode psychosis.
The RAISE program led to the development of the NAVIGATE model, a coordinated specialty care (CSC) approach that integrates medication management, psychotherapy, family education, and supported employment and education services. This model has been widely recognized as a major advancement in early intervention for schizophrenia and has influenced mental health policy and service delivery frameworks in the United States and beyond. It represents a shift toward comprehensive, team-based care designed to improve long-term recovery outcomes during the critical early stages of illness.
In addition to his work in early intervention, Dr. Kane is internationally known for his pioneering research on clozapine, one of the most important antipsychotic medications used in the treatment of treatment-resistant schizophrenia. His studies have helped establish clozapine’s efficacy in patients who do not respond to other antipsychotic drugs, while also carefully evaluating its safety profile and clinical management considerations. This work has had a lasting impact on treatment guidelines and clinical decision-making in psychiatry.
Dr. Kane has also contributed extensively to understanding the therapeutic and adverse effects of psychotropic medications more broadly. His research has consistently emphasized the importance of balancing efficacy with safety, helping clinicians better evaluate benefit-to-risk profiles when selecting treatments for individuals with severe psychiatric conditions. This work has played a key role in shaping evidence-based prescribing practices in psychiatric medicine.
Over the course of his career, Dr. Kane has authored more than 950 peer-reviewed scientific publications, making him one of the most prolific contributors in the field of psychiatry. His work has appeared in leading medical and scientific journals and has been widely cited by researchers, clinicians, and policymakers. Through this extensive body of literature, he has helped shape modern understanding of schizophrenia pathophysiology, treatment strategies, and long-term care models.
Beyond his research contributions, Dr. Kane has also played a significant leadership role in professional psychiatric organizations. He has served as president of several major societies, including the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society itself. These leadership positions reflect his influence not only as a researcher but also as a key figure in shaping the direction of psychiatric research and education globally.
Colleagues at the Feinstein Institutes emphasized the profound impact of Dr. Kane’s work on both science and patient care. Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes for Medical Research and Karches Family Distinguished Chair in Medical Research, praised Dr. Kane’s lifelong dedication to advancing the field. He noted that Dr. Kane’s pioneering research has not only transformed the scientific landscape of schizophrenia but has also directly improved the lives of countless patients and families around the world. He described the Lifetime Achievement Award as a fitting recognition of Dr. Kane’s extraordinary commitment to mental and behavioral health research.
The recognition from SIRS underscores the global significance of Dr. Kane’s contributions at a time when mental health disorders are increasingly recognized as a major public health challenge. Schizophrenia, in particular, remains a complex and debilitating condition that affects millions of people worldwide and continues to require innovative approaches to treatment and care delivery. Dr. Kane’s work has been central to shifting the field toward earlier intervention, integrated care models, and evidence-based treatment strategies that prioritize long-term recovery.
As the field of psychiatry continues to evolve, Dr. Kane’s legacy remains deeply embedded in both scientific research and clinical practice. His contributions have helped redefine how schizophrenia is understood and treated, influencing generations of clinicians and researchers. The 2026 SIRS Lifetime Achievement Award serves as a testament to a career dedicated not only to scientific excellence but also to improving the lives of individuals and families affected by one of the most challenging mental health disorders.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research.
We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program.
